ESPE Abstracts (2019) 92 P2-61

1Unidad de Endocrinología Pediátrica. Hospital Clínico Universitario de Santiago de Compostela. USC. IDIS, Santiago de Compostela, Spain. 2Dpto de Pediatría. Universidad de Santiago de Compostela, Santiago de Compostela, Spain. 3Servicio de Traumatología. Hospital Clínico Universitario de Santiago de Compostela. USC, Santiago de Compostela, Spain. 4Universidad de Santiago de Compostela, Santiago de Compostela, Spain. 5Fundación Publica Galega de Medicina Xenómica, Santiago de Compostela, Spain

Osteogenesis imperfecta (OI) is a rare, hereditary bone dysplasia with a broad clinical spectrum that includes skeletal and extra-skeletal manifestations. It is genetically heterogeneous and there are multiple described mutations that explain the clinical variability of this entity and make it difficult to establish a genotype-phenotype correlation.

Objectives: To evaluate the clinical and genetic characteristics of the patient with OI.

Patients and Methods: Clinical and genetic descriptive study of a series of cases diagnosed of OI in a Pediatric Endocrinology unit in the last decade. Genetic study: The genes COL1A1, COL1A2, CRTAP, FKBP10, LEPRE1, PPIB, SERPINF1, SERPINH1, SP7 were studied by sequencing NGS (SOLID 5500XL). Confirmation of the mutation by PCR amplification and subsequent sequencing.

Results: In the period studied, 6 patients (2 men and 4 girls) were diagnosed of OI with variable phenotype . The study of them and their respective families demonstrate the clinical and genetic heterogeneity characteristic of the disease. Case 1 presents a severe phenotype with numerous bone fractures and deformities. Case 2 is a mild form, with sensorineural deafness and without fractures. The remaining 4 cases are moderate intensity forms of the disease. In all cases, the clinical diagnosis was genetically confirmed, finding mutations in the COL1A1 and COL1A2 genes with AD inheritance and in one of the cases was de novo mutation. Three new mutations associated with OI have been described: c.1207G> T (p.Gly403Cys) in exon 22 of the COL1A2 gene with AD inheritance (case 1). A duplication in heterozygosis of exons 1-49 de novo of the COL1A1 gene (case 5). And, also for the first time, in exon 41 of COL1A1 the mutation c.2938G> A (p.Gly980Ser) in case 6.

Conclusions: All patients studied with a variable phenotype of OI, as well as some members of their families, show genetic alterations in some of the genes related to this disease that confirm the diagnosis. Our group have described for the first time three of the mutations: two in the COL1A1 gene with moderate phenotype of the disease and another in COL1A2, in a patient with a severe OI phenotype.

Volume 92

58th Annual ESPE

Vienna, Austria
19 Sep 2019 - 21 Sep 2019

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts